title: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
abstract: Paraffin blocks and clinical data from 521 patients with lymphocyte predominance Hodgkin disease (LPHD) diagnosed between 1970 and 1994 were collected from 16 European and United States oncological centers to establish the pathologic and clinical characteristics of a large patient cohort, to determine how frequent T-cell-rich large B-cell lymphoma (TCRLBCL) is among LPHD, and to find differential diagnostic criteria distinguishing between the 2 lymphoma categories. For this purpose, conventionally and immunohistologically stained sections were reviewed by a panel of hematopathologists. The diagnosis of LPHD was confirmed in only 219 of the 388 assessable cases (56.5%). This low confirmation rate was due mainly to the presence of a new variant of classical Hodgkin disease (CHD), which resembled, in terms of nodular growth and lymphocyte-richness, nodular LPHD and, in terms of the immunophenotype of the tumor cells, CHD and was designated nodular lymphocyte-rich CHD (NLRCHD). The nodules of LRCHD consisted-as in nodular LPHD-predominantly of B cells but differed from those present in LPHD in that they represented expanded mantle zones with atrophic germinal centers. Clinically, patients with LPHD and NLRCHD showed similar disease characteristics at presentation but differed in the frequency of multiple relapses and prognosis after relapse. Patients with LPHD and NLRCHD clearly differed from patients with CHD with nodular sclerosis or mixed cellularity, as they presented with an earlier disease stage and infrequent mediastinal involvement. As 97% of the LPHD cases showed a complete or partial nodular growth pattern, their differentiation from TCRLBCL was a rare problem in the present series. (Blood. 2000;96:1889-1899)
authors.affiliation: Institute of Pathology, Klinikum Benjamin Franklin, Free University Berlin, Berlin, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Anagnostopoulos
authors.forename: M L
authors.initials: ML
authors.lastname: Hansmann
authors.forename: K
authors.initials: K
authors.lastname: Franssila
authors.forename: M
authors.initials: M
authors.lastname: Harris
authors.forename: N L
authors.initials: NL
authors.lastname: Harris
authors.forename: E S
authors.initials: ES
authors.lastname: Jaffe
authors.forename: J
authors.initials: J
authors.lastname: Han
authors.forename: J M
authors.initials: JM
authors.lastname: van Krieken
authors.forename: S
authors.initials: S
authors.lastname: Poppema
authors.forename: T
authors.initials: T
authors.lastname: Marafioti
authors.forename: J
authors.initials: J
authors.lastname: Franklin
authors.forename: M
authors.initials: M
authors.lastname: Sextro
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: H
authors.initials: H
authors.lastname: Stein
mesh_terms: D000293:Adolescent; D000328:Adult; D018951:Antigens, CD20 / Q000032:analysis; D020031:Epstein-Barr Virus Infections / Q000473:pathology / Q000821:virology; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006689:Hodgkin Disease / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017403:In Situ Hybridization; D017730:Ki-1 Antigen / Q000032:analysis; D016256:Lewis X Antigen / Q000032:analysis; D008214:Lymphocytes / Q000737:chemistry / Q000473:pathology*; D008223:Lymphoma / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D018951:Antigens, CD20; D017730:Ki-1 Antigen; D016256:Lewis X Antigen; D012367:RNA, Viral